首页> 美国卫生研究院文献>other >Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter Randomized Double-Blind Parallel-Group Placebo Controlled Trial

【2h】

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter Randomized Double-Blind Parallel-Group Placebo Controlled Trial

机译：雷贝格列酮单药治疗24周内2型糖尿病患者的疗效和安全性：多中心随机双盲平行组安慰剂对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveThe aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes.

机译：目的这项研究的目的是评估与安慰剂作为单一疗法治疗2型糖尿病患者相比，新型过氧化物酶体增殖物激活的受体γ激动剂洛贝格列酮的降糖和调脂作用以及安全性。

著录项

期刊名称 other
作者
Sin Gon Kim; Doo Man Kim; Jeong-Taek Woo; Hak Chul Jang; Choon Hee Chung; Kyung Soo Ko; Jeong Hyun Park; Yong Soo Park; Sang Jin Kim; Dong Seop Choi;
展开▼
作者单位

展开▼
年(卷),期 -1(9),4
年度 -1
页码 e92843
总页数 7
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [J] . Rosenstock J, Brazg R, Andryuk PJ, Clinical therapeutics . 2006,第10期

机译：二肽基肽酶-4抑制剂西他列汀与正在进行的吡格列酮治疗对2型糖尿病患者的疗效和安全性：一项为期24周，多中心，随机，双盲，安慰剂对照的平行组研究。
2. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study [J] . Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, Cardiovascular Diabetology . 2014,第1期

机译：新型钠/葡萄糖共转运蛋白2抑制剂tofogliflozin在日本2型糖尿病患者中单药治疗的有效性和安全性：一项2期和3期随机，安慰剂对照，双盲，平行组比较研究
3. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial [J] . Sorli Christopher, Harashima Shin-ichi, Tsoukas George M., The lancet. Diabetes & endocrinology. . 2017,第4期

机译：患有2型糖尿病患者的一次每周半蛋白质单药治疗的疗效和安全性（持续1）：双盲，随机，安慰剂控制，平行群，跨国，多元相3A试验
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. A randomized placebo-controlled trial of pioglitazone to improve metabolic control in adolescents with type 1 diabetes mellitus. [D] . Zdravkovic, Vera. 2005

机译：吡格列酮对改善1型糖尿病青少年的代谢控制的随机安慰剂对照试验。
6. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized placebo-controlled double-blind parallel-group comparative study [O] . Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, 2014

机译：新型钠/葡萄糖共转运蛋白2抑制剂tofogliflozin在日本2型糖尿病患者中单药治疗的有效性和安全性：一项2期和3期随机安慰剂对照双盲平行组比较研究
7. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. [O] . Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, 2014

机译：Lobeglitazone单药治疗对2型糖尿病患者24周的疗效和安全性：多中心，随机，双盲，平行组，安慰剂对照试验。

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter Randomized Double-Blind Parallel-Group Placebo Controlled Trial

摘要

著录项

相似文献

相关主题

期刊订阅